Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

Positive expression results presented from the casimersen arm of the ESSENCE study

March 29, 2019

VALZ-pilot as the first clinical study to evaluate antiviral valaciclovir for the treatment of AD

March 29, 2019

Promising preclinical and first-in-human data presented for PRI-002

March 29, 2019

The many shapes of tauopathy

March 29, 2019

Biohaven begins phase II study of BHV-3500 for acute treatment of migraine

March 28, 2019

New monoglyceride lipase inhibitors described by Abide Therapeutics

March 28, 2019

Kalyra Pharmaceuticals starts phase I study of KP-1199

March 28, 2019

Daiichi Sankyo initiates dosing in phase III AMELA study of mirogabalin

March 28, 2019

Probiotics for treating autism prepared at Beijing Jinfeng Labs Technology

March 28, 2019

Novel quinolylnitrone with antioxidant neuroprotective effect for ischemic stroke

March 28, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 22, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
Unmasking the X: EPAC2 shifts the fragile X landscape
BioWorld
Researchers at UCLA have shown that divergent neuronal signaling in fragile X mice converges on EPAC2, a druggable target whose inhibition restores circuit...
Recludix presents STAT1/3 inhibitors for dermatological diseases
BioWorld Science
Recludix Pharma Inc. recently presented data on their new STAT1/3 inhibitors REX-6553 and REX-6547 for treating dermatological inflammatory skin diseases.